BTB Therapeutics, Inc.
Escondido, US · Founded 2024 · Delaware corporation · 1 known investors
BTB Therapeutics develops a non-opioid analgesic aimed at addressing the opioid crisis, along with a pipeline of RNA-modifying compounds for rare genetic diseases and to enhance cancer immunotherapy. The company is based on transcriptomics drug discovery programs from Kyoto University, with a US parent and an operating subsidiary in Kyoto, Japan.
BiotechHealthtechMedical Devices
Founders & leadership
TK
Takashi KiyoizumiCEO, Director of the Board
MH
Masatoshi HagiwaraChief Scientific Officer, Director of the Board (founder of BTB Therapeutics Co., Ltd.)
KW
Kenneth W. LockeChief Development Officer
Investors · 1
Reported raises · per SEC filings
Form D private placements▶$3.4MraisedDec 2025 · 4 investors · PharmaceuticalsRule 506(b)
▶$3.4MraisedDec 2025 · 4 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Masatoshi HagiwaraDirector
- Nobuhiro YagiDirector
- David SnyderDirector
- Takashi KiyoizumiExecutive Officer, Director
- Offering amount
- $7.4M
- Amount sold
- $3.4M
- Proceeds to insiders
- $250K
- First sale
- Nov 2025
- Incorporated
- Corporation, Delaware, 2024
- Federal exemptions
- 06b
▶$3.3MraisedFeb 2025 · 10 investors · PharmaceuticalsRule 506(b)
▶$3.3MraisedFeb 2025 · 10 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Takashi KiyoizumiExecutive Officer, Director
- Offering amount
- $3.3M
- Amount sold
- $3.3M
- First sale
- Jan 2025
- Incorporated
- Corporation, Delaware, 2024
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.